Clinical trials: Dyslipidemias
Primary Hypercholesterolemia
An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
The study observes real world patients with primary hypercholesterolemia who receive a fixed dose combination therapy with atorvastatin and ezetimibe for 24 weeks; collects and analyzes data related to efficacy and safety of the…
- Trial name
- LITE (NCT05559606)
- Where
- South Korea
- Volunteers
- 1,839 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy
Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults
The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc.
- Trial name
- NCT00782548
- Testing
- KADIAN (morphine sulfate sustained-release) capsules, Avinza (morphine sulfate sustained-release) capsules
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Hypertension, Dyslipidemias
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT04074551
- Testing
- HCP1701, Losartan, Amlodipine
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Homozygous Familial Hypercholesterolemia
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
- Trial name
- ORION-2 (NCT02963311)
- Testing
- ALN-PCSSC, Standard of Care
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- The Medicines Company
Hypertriglyceridemia
A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in adults with moderate hypertriglyceridemia and diabetic kidney disease.
- Trial name
- NCT07848880
- Testing
- DR10624 Injection
- Where
- 2 sites in China
- Volunteers
- 315 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Coronary Artery Disease, Dyslipidemia
The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low…
- Trial name
- SUSTAIN (NCT01423188)
- Testing
- RVX000222
- Where
- 25 sites in South Africa
- Volunteers
- 176 people
- Sponsor
- Resverlogix Corp
Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVEII (NCT02009865)
- Testing
- Epanova, Olive Oil
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 379 people
- Sponsor
- AstraZeneca
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Hypercholesterolemia
Single Dose Study of PF-06815345 in Healthy Subjects
The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult…
- Trial name
- NCT02654899
- Testing
- PF-06815345
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dyslipidemia
ALN-APOC3 in Adult Participants With Dyslipidemia
This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol)…
- Trial name
- NCT06784349
- Testing
- ALN-APOC3
- Where
- Moldova
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Dyslipidemias
Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia
- Trial name
- NCT03009721
- Testing
- Other: Not applicable-observational study
- Where
- South Korea
- Volunteers
- 9,707 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Hypercholesterolemia
K-924 Phase III Confirmatory Study
A multicenter, active-controlled, randomized, double-blind comparative study to compare the efficacy and safety of K-924 LD tablet or K-924 HD tablet to pitavastatin 2 mg or 4 mg in patienta with hypercholesterolemia.
- Trial name
- NCT04289649
- Testing
- K-924 LD, K-924 HD
- Where
- 3 sites in Japan
- Volunteers
- 293 people
- Sponsor
- Kowa Company, Ltd.
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of…
- Trial name
- NCT02569814
- Testing
- Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia
Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
The purpose of the survey is to evaluate the efficacy of treatment of hypercholesterolemia in Polish patients who are currently on lipid- lowering pharmacological therapy .
- Trial name
- CEPHEUS (NCT01243255)
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
Hypercholesterolemia
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of statin therapy with or without ezetimibe.
- Trial name
- NCT04164888
- Testing
- CIVI 007
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Civi Biopharma, Inc.
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia
- Trial name
- NCT00268697
- Testing
- Lapaquistat acetate, Lapaquistat acetate and ezetimibe, Ezetimibe
- Where
- 9 sites in Estonia, Latvia and 2 more
- Volunteers
- 1,267 people
- Sponsor
- Takeda
Mixed Dyslipidemia
A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
Post-marketing surveillance of Rosuvastatin/Ezetimibe
- Trial name
- NCT03648788
- Testing
- NA (Observation study)
- Volunteers
- 600 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.